Green Tea, EGCG, and Cancer Prevention: What the Evidence Shows

Green tea (Camellia sinensis) has been consumed in East Asia for over 4,000 years and is the most widely consumed beverage in the world after water. Its health properties are attributed primarily to a class of polyphenols called catechins, of which EGCG (epigallocatechin-3-gallate) is the most abundant and biologically active — comprising approximately 50–80% of the total catechin content of green tea. EGCG is a potent antioxidant (estimated to be 25–100 times more potent than vitamins C and E in certain assays) and has demonstrated anti-cancer activity in thousands of laboratory studies. The epidemiological interest in green tea and cancer was sparked by observations that Japanese populations — among the world's highest green tea consumers — have significantly lower rates of stomach, oesophageal, and certain other cancers compared to Western populations.

Mechanisms of Anti-Cancer Activity. EGCG has demonstrated anti-cancer activity through multiple mechanisms: (1) Antioxidant protection — EGCG scavenges free radicals and chelates metal ions that catalyse oxidative DNA damage. (2) Apoptosis induction — EGCG activates caspase-3 and inhibits Bcl-2, promoting programmed cell death in cancer cells while sparing normal cells. (3) Cell cycle arrest — EGCG inhibits CDK2 and CDK4, arresting cancer cells in the G1 phase. (4) Anti-angiogenesis — EGCG inhibits VEGF and matrix metalloproteinases (MMPs), reducing tumour blood vessel formation and invasion. (5) Telomerase inhibition — EGCG inhibits telomerase activity in cancer cells, which depend on telomerase for immortality. (6) Proteasome inhibition — EGCG inhibits the 26S proteasome in cancer cells, triggering apoptosis through accumulation of pro-apoptotic proteins.

Epidemiological Evidence. The epidemiological evidence for green tea and cancer is strongest for gastric cancer, oesophageal cancer, and prostate cancer. A 2006 prospective cohort study of 49,920 Japanese adults (Inoue et al., Annals of Epidemiology) found that drinking 5 or more cups of green tea per day was associated with a 48% lower risk of gastric cancer in women. A 2004 meta-analysis found that high green tea consumption was associated with a 22% reduction in lung cancer risk. A 2006 RCT by Bettuzzi et al. (Cancer Research) found that 600mg/day of green tea catechins for 12 months reduced the progression of high-grade prostate intraepithelial neoplasia (HGPIN) to prostate cancer by 90% compared to placebo — one of the most striking cancer prevention trial results for any natural compound.

Clinical Trials: Promising Early Results. Beyond the Bettuzzi prostate trial, several other clinical trials have investigated EGCG in cancer: A 2013 Phase II trial by Shanafelt et al. found that EGCG supplementation produced a 50% or greater reduction in absolute lymphocyte count in 33% of patients with early-stage chronic lymphocytic leukaemia (CLL). A 2012 trial found that green tea extract reduced the recurrence of colorectal adenomas (precancerous polyps) in patients with a history of colorectal cancer. These are small, early-phase trials — they establish safety and preliminary efficacy signals, not proof of clinical benefit.

Practical Guidance. For general health and potential cancer-preventive benefit: 3–5 cups of high-quality green tea per day (matcha provides the highest EGCG content, as the whole leaf is consumed). Brew at 70–80°C (not boiling) to preserve catechin content. Add lemon juice — vitamin C significantly improves EGCG bioavailability and stability. Avoid drinking green tea with milk — milk proteins bind catechins and reduce bioavailability. For supplementation: 400–800mg/day of standardised green tea extract (standardised to 50% EGCG), taken with food to reduce the risk of gastrointestinal side effects. Important caution: high-dose green tea extract supplements (above 800mg/day EGCG) have been associated with rare cases of liver toxicity — use the lowest effective dose and avoid combining multiple high-dose catechin supplements.